Advertisement
Advertisement
EVO
Evotec SE - ADR
1.32
USDSponsored
-0.13
-8.97%
Nov 20, 15:56 UTC -5
Closed
After-Market
1.31
-0.01
-0.38%
Evotec SE - ADR (EVO) Earnings
EVO Earnings Reports
Positive Surprise Ratio
EVO beat 17 of 41 last estimates.
41%
Next Report
Date of Next Report
Apr 06, 2027
Estimate for Q4 26 (Revenue/ EPS)
$140.69M
/-$0.44
Implied change from Q3 26 (Revenue/ EPS)
-14.69%
/+193.33%
Implied change from Q4 25 (Revenue/ EPS)
-44.45%
/-650.00%
Evotec SE - ADR earnings per share and revenue
On Nov 05, 2026, EVO reported earnings of -0.15 USD per share (EPS) for Q3 26, beating the estimate of -0.34 USD, resulting in a 56.32% surprise. Revenue reached 164.93 million, compared to an expected 130.29 million, with a 26.58% difference. The market reacted with a +13.06% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.44 USD, with revenue projected to reach 140.69 million USD, implying an increase of 193.33% EPS, and decrease of -14.69% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%

Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%

Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%

Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%

NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%

Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%

Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%

Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%

Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%

60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
What were Evotec SE - ADR's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Evotec SE - ADR reported EPS of -$0.15, beating estimates by 56.32%, and revenue of $164.93M, 26.58% above expectations.
How did the market react to Evotec SE - ADR's Q3 2026 earnings?
The stock price moved up 13.06%, changed from $1.57 before the earnings release to $1.77 the day after.
When is Evotec SE - ADR expected to report next?
The next earning report is scheduled for Apr 06, 2027.
What are the forecasts for Evotec SE - ADR's next earnings report?
Based on --
analysts, Evotec SE - ADR is expected to report EPS of -$0.44 and revenue of $140.69M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.